ID   VAV_HUMAN               Reviewed;         845 AA.
AC   P15498; B4DVK9; M0QXX6; Q15860;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 4.
DT   03-AUG-2022, entry version 240.
DE   RecName: Full=Proto-oncogene vav;
GN   Name=VAV1; Synonyms=VAV;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF CYS-529.
RX   PubMed=2069873;
RA   Coppola J., Bryant S., Koda T., Conway D., Barbacid M.;
RT   "Mechanism of activation of the vav protooncogene.";
RL   Cell Growth Differ. 2:95-105(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10760587; DOI=10.1016/s0167-4781(00)00008-7;
RA   Denkinger D.J., Borges C.R., Butler C.L., Cushman A.M., Kawahara R.S.;
RT   "Genomic organization and regulation of the vav proto-oncogene.";
RL   Biochim. Biophys. Acta 1491:253-262(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-61.
RX   PubMed=2005887; DOI=10.1128/mcb.11.4.1912-1920.1991;
RA   Katzav S., Cleveland J.L., Heslop H.E., Pulido D.;
RT   "Loss of the amino-terminal helix-loop-helix domain of the vav proto-
RT   oncogene activates its transforming potential.";
RL   Mol. Cell. Biol. 11:1912-1920(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 51-813 (ISOFORM 2).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 68-845 (ISOFORM 1).
RX   PubMed=2477241; DOI=10.1002/j.1460-2075.1989.tb08354.x;
RA   Katzav S., Martin-Zanca D., Barbacid M.;
RT   "vav, a novel human oncogene derived from a locus ubiquitously expressed in
RT   hematopoietic cells.";
RL   EMBO J. 8:2283-2290(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 299-837 (ISOFORM 1).
RA   Romero F.;
RL   Submitted (JAN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 299-334 (ISOFORM 1).
RX   PubMed=7478592;
RA   Ramos-Morales F., Romero F., Schweighoffer F., Bismuth G., Camonis J.,
RA   Tortolero M., Fischer S.;
RT   "The proline-rich region of Vav binds to Grb2 and Grb3-3.";
RL   Oncogene 11:1665-1669(1995).
RN   [9]
RP   SIMILARITY TO CDC24 FAMILY.
RX   PubMed=1565462;
RA   Adams J.M., Houston H., Allen J., Lints T., Harvey R.;
RT   "The hematopoietically expressed vav proto-oncogene shares homology with
RT   the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24)
RT   involved in cytoskeletal organization.";
RL   Oncogene 7:611-618(1992).
RN   [10]
RP   INTERACTION WITH SYK, AND MUTAGENESIS OF ARG-696.
RX   PubMed=8986718; DOI=10.1016/s1074-7613(00)80273-3;
RA   Deckert M., Tartare-Deckert S., Couture C., Mustelin T., Altman A.;
RT   "Functional and physical interactions of Syk family kinases with the Vav
RT   proto-oncogene product.";
RL   Immunity 5:591-604(1996).
RN   [11]
RP   INTERACTION WITH CBLB.
RX   PubMed=9399639; DOI=10.1038/sj.onc.1201430;
RA   Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., Barbacid M.;
RT   "Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated
RT   c-Jun N-terminal kinase activation.";
RL   Oncogene 15:2511-2520(1997).
RN   [12]
RP   INTERACTION WITH BLNK; PLCG1; GRB2 AND NCK1.
RX   PubMed=9697839; DOI=10.1016/s1074-7613(00)80591-9;
RA   Fu C., Turck C.W., Kurosaki T., Chan A.C.;
RT   "BLNK: a central linker protein in B cell activation.";
RL   Immunity 9:93-103(1998).
RN   [13]
RP   INTERACTION WITH SIAH2.
RX   PubMed=10207103; DOI=10.1128/mcb.19.5.3798;
RA   Germani A., Romero F., Houlard M., Camonis J., Gisselbrecht S., Fischer S.,
RA   Varin-Blank N.;
RT   "hSiah2 is a new Vav binding protein which inhibits Vav-mediated signaling
RT   pathways.";
RL   Mol. Cell. Biol. 19:3798-3807(1999).
RN   [14]
RP   PHOSPHORYLATION BY FYN.
RX   PubMed=11005864; DOI=10.1073/pnas.97.20.10923;
RA   Huang J., Tilly D., Altman A., Sugie K., Grey H.M.;
RT   "T-cell receptor antagonists induce Vav phosphorylation by selective
RT   activation of Fyn kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:10923-10929(2000).
RN   [15]
RP   INTERACTION WITH DOCK2.
RX   PubMed=12393632; DOI=10.1182/blood-2001-11-0032;
RA   Nishihara H., Maeda M., Oda A., Tsuda M., Sawa H., Nagashima K., Tanaka S.;
RT   "DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell
RT   lines.";
RL   Blood 100:3968-3974(2002).
RN   [16]
RP   INTERACTION WITH SHB.
RX   PubMed=12084069; DOI=10.1046/j.1432-1033.2002.03008.x;
RA   Lindholm C.K., Henriksson M.L., Hallberg B., Welsh M.;
RT   "Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells.";
RL   Eur. J. Biochem. 269:3279-3288(2002).
RN   [17]
RP   INTERACTION WITH SH2B2.
RX   PubMed=12400014; DOI=10.1038/sj.onc.1205927;
RA   Yabana N., Shibuya M.;
RT   "Adaptor protein APS binds the NH2-terminal autoinhibitory domain of
RT   guanine nucleotide exchange factor Vav3 and augments its activity.";
RL   Oncogene 21:7720-7729(2002).
RN   [18]
RP   INTERACTION WITH ITK.
RX   PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385;
RA   Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A.,
RA   Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.;
RT   "Kinase-independent functions for Itk in TCR-induced regulation of Vav and
RT   the actin cytoskeleton.";
RL   J. Immunol. 174:1385-1392(2005).
RN   [19]
RP   INTERACTION WITH NEK3.
RX   PubMed=15618286; DOI=10.1210/me.2004-0443;
RA   Miller S.L., DeMaria J.E., Freier D.O., Riegel A.M., Clevenger C.V.;
RT   "Novel association of Vav2 and Nek3 modulates signaling through the human
RT   prolactin receptor.";
RL   Mol. Endocrinol. 19:939-949(2005).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-826, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [21]
RP   INTERACTION WITH ZNF655/VIK.
RX   PubMed=15558030; DOI=10.1038/sj.onc.1208043;
RA   Houlard M., Romero-Portillo F., Germani A., Depaux A., Regnier-Ricard F.,
RA   Gisselbrecht S., Varin-Blank N.;
RT   "Characterization of VIK-1: a new Vav-interacting Kruppel-like protein.";
RL   Oncogene 24:28-38(2005).
RN   [22]
RP   INTERACTION WITH PTK2B/PYK2.
RX   PubMed=19207108; DOI=10.1042/bj20090037;
RA   Gao C., Blystone S.D.;
RT   "A Pyk2-Vav1 complex is recruited to beta3-adhesion sites to initiate Rho
RT   activation.";
RL   Biochem. J. 420:49-56(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INTERACTION WITH CRACR2A.
RX   PubMed=27016526; DOI=10.1126/scisignal.aac9171;
RA   Srikanth S., Kim K.D., Gao Y., Woo J.S., Ghosh S., Calmettes G., Paz A.,
RA   Abramson J., Jiang M., Gwack Y.;
RT   "A large Rab GTPase encoded by CRACR2A is a component of subsynaptic
RT   vesicles that transmit T cell activation signals.";
RL   Sci. Signal. 9:ra31-ra31(2016).
RN   [25]
RP   STRUCTURE BY NMR OF 661-775.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH2 domain of human proto-oncogene protein
RT   VAV1.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: Couples tyrosine kinase signals with the activation of the
CC       Rho/Rac GTPases, thus leading to cell differentiation and/or
CC       proliferation.
CC   -!- SUBUNIT: Interacts with SHB (PubMed:12084069). Interacts with SH2B2,
CC       GRB2, GRB3, DOCK2, SLA, TEC and ZNF655/VIK (PubMed:12393632,
CC       PubMed:12400014, PubMed:15558030). Interacts with SIAH2; without
CC       leading to its degradation (PubMed:10207103). Associates with BLNK,
CC       PLCG1, GRB2 and NCK1 in a B-cell antigen receptor-dependent fashion
CC       (PubMed:9697839). Interacts with CBLB; which inhibits tyrosine
CC       phosphorylation and down-regulates activity (PubMed:9399639). May
CC       interact with CCPG1. Interacts with CLNK. Interacts with THEMIS2 (By
CC       similarity). Interacts with NEK3 and this interaction is prolactin-
CC       dependent (PubMed:15618286). Interacts with ITK (PubMed:15661896).
CC       Interacts with PTK2B/PYK2 (By similarity). Interacts with HCK.
CC       Interacts with PTK2B/PYK2 (PubMed:19207108). Interacts (via SH2 domain)
CC       with SYK (PubMed:8986718). Interacts with ANKRD54. Interacts with CD6
CC       (By similarity). Interacts with isoform 2 of CRACR2A (PubMed:27016526).
CC       {ECO:0000250|UniProtKB:P27870, ECO:0000269|PubMed:10207103,
CC       ECO:0000269|PubMed:12084069, ECO:0000269|PubMed:12393632,
CC       ECO:0000269|PubMed:12400014, ECO:0000269|PubMed:15558030,
CC       ECO:0000269|PubMed:15618286, ECO:0000269|PubMed:15661896,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:27016526,
CC       ECO:0000269|PubMed:8986718, ECO:0000269|PubMed:9399639,
CC       ECO:0000269|PubMed:9697839}.
CC   -!- INTERACTION:
CC       P15498; Q8IZP0: ABI1; NbExp=2; IntAct=EBI-625518, EBI-375446;
CC       P15498; P00519: ABL1; NbExp=5; IntAct=EBI-625518, EBI-375543;
CC       P15498; Q13480: GAB1; NbExp=2; IntAct=EBI-625518, EBI-517684;
CC       P15498; P62993: GRB2; NbExp=3; IntAct=EBI-625518, EBI-401755;
CC       P15498; Q07666: KHDRBS1; NbExp=3; IntAct=EBI-625518, EBI-1364;
CC       P15498; Q13094: LCP2; NbExp=9; IntAct=EBI-625518, EBI-346946;
CC       P15498; P63000: RAC1; NbExp=2; IntAct=EBI-625518, EBI-413628;
CC       P15498; P78314: SH3BP2; NbExp=8; IntAct=EBI-625518, EBI-727062;
CC       P15498; Q8N720: ZNF655; NbExp=5; IntAct=EBI-625518, EBI-625509;
CC       P15498; P08487: PLCG1; Xeno; NbExp=4; IntAct=EBI-625518, EBI-8013886;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15498-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15498-2; Sequence=VSP_047563;
CC   -!- TISSUE SPECIFICITY: Widely expressed in hematopoietic cells but not in
CC       other cell types.
CC   -!- DOMAIN: The DH domain is involved in interaction with CCPG1.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues by HCK in response to IFNG and
CC       bacterial lipopolysaccharide (LPS) (By similarity). Phosphorylated by
CC       FYN. {ECO:0000250, ECO:0000269|PubMed:11005864}.
CC   -!- MISCELLANEOUS: 'Vav' stands for the sixth letter of the Hebrew
CC       alphabet.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62721.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA34383.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VAV1ID195ch19p13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF030227; AAC25011.1; -; Genomic_DNA.
DR   EMBL; AF030201; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030202; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030203; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030204; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030205; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030206; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030207; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030208; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030209; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030210; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030211; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030212; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030213; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030214; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030215; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030216; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030217; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030218; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030219; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030220; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030221; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030222; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030223; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030224; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030225; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AF030226; AAC25011.1; JOINED; Genomic_DNA.
DR   EMBL; AC010647; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020895; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020954; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022156; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M59834; AAA63267.1; -; Genomic_DNA.
DR   EMBL; AK301128; BAG62721.1; ALT_INIT; mRNA.
DR   EMBL; X16316; CAA34383.1; ALT_FRAME; mRNA.
DR   EMBL; X83931; CAA58783.1; -; mRNA.
DR   CCDS; CCDS12174.1; -. [P15498-1]
DR   CCDS; CCDS59342.1; -. [P15498-2]
DR   PIR; B39576; TVHUVV.
DR   RefSeq; NP_001245136.1; NM_001258207.1. [P15498-2]
DR   RefSeq; NP_005419.2; NM_005428.3. [P15498-1]
DR   PDB; 2CRH; NMR; -; A=629-775.
DR   PDB; 2LCT; NMR; -; A=664-767.
DR   PDB; 2MC1; NMR; -; A=664-767.
DR   PDB; 2ROR; NMR; -; A=629-775.
DR   PDB; 3BJI; X-ray; 2.60 A; A/B=189-565.
DR   PDB; 3KY9; X-ray; 2.73 A; A/B=2-584.
DR   PDB; 6NEW; X-ray; 2.50 A; A=170-575.
DR   PDB; 6NF1; X-ray; 2.60 A; A=2-575.
DR   PDB; 6NFA; X-ray; 2.70 A; A=170-575.
DR   PDBsum; 2CRH; -.
DR   PDBsum; 2LCT; -.
DR   PDBsum; 2MC1; -.
DR   PDBsum; 2ROR; -.
DR   PDBsum; 3BJI; -.
DR   PDBsum; 3KY9; -.
DR   PDBsum; 6NEW; -.
DR   PDBsum; 6NF1; -.
DR   PDBsum; 6NFA; -.
DR   AlphaFoldDB; P15498; -.
DR   BMRB; P15498; -.
DR   SMR; P15498; -.
DR   BioGRID; 113252; 188.
DR   CORUM; P15498; -.
DR   DIP; DIP-1061N; -.
DR   IntAct; P15498; 139.
DR   MINT; P15498; -.
DR   STRING; 9606.ENSP00000472929; -.
DR   BindingDB; P15498; -.
DR   ChEMBL; CHEMBL3259472; -.
DR   iPTMnet; P15498; -.
DR   PhosphoSitePlus; P15498; -.
DR   BioMuta; VAV1; -.
DR   DMDM; 13124807; -.
DR   CPTAC; CPTAC-1226; -.
DR   CPTAC; CPTAC-1227; -.
DR   EPD; P15498; -.
DR   jPOST; P15498; -.
DR   MassIVE; P15498; -.
DR   MaxQB; P15498; -.
DR   PaxDb; P15498; -.
DR   PeptideAtlas; P15498; -.
DR   PRIDE; P15498; -.
DR   ProteomicsDB; 53143; -. [P15498-1]
DR   Antibodypedia; 665; 764 antibodies from 42 providers.
DR   DNASU; 7409; -.
DR   Ensembl; ENST00000596764.5; ENSP00000469450.1; ENSG00000141968.8. [P15498-2]
DR   Ensembl; ENST00000602142.6; ENSP00000472929.1; ENSG00000141968.8. [P15498-1]
DR   GeneID; 7409; -.
DR   KEGG; hsa:7409; -.
DR   MANE-Select; ENST00000602142.6; ENSP00000472929.1; NM_005428.4; NP_005419.2.
DR   UCSC; uc002mfu.3; human. [P15498-1]
DR   CTD; 7409; -.
DR   DisGeNET; 7409; -.
DR   GeneCards; VAV1; -.
DR   HGNC; HGNC:12657; VAV1.
DR   HPA; ENSG00000141968; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 164875; gene.
DR   neXtProt; NX_P15498; -.
DR   OpenTargets; ENSG00000141968; -.
DR   PharmGKB; PA37280; -.
DR   VEuPathDB; HostDB:ENSG00000141968; -.
DR   eggNOG; KOG2996; Eukaryota.
DR   GeneTree; ENSGT00940000159125; -.
DR   InParanoid; P15498; -.
DR   OMA; PYISRPT; -.
DR   PhylomeDB; P15498; -.
DR   TreeFam; TF316171; -.
DR   PathwayCommons; P15498; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9027284; Erythropoietin activates RAS.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9748787; Azathioprine ADME.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P15498; -.
DR   SIGNOR; P15498; -.
DR   BioGRID-ORCS; 7409; 13 hits in 1071 CRISPR screens.
DR   ChiTaRS; VAV1; human.
DR   EvolutionaryTrace; P15498; -.
DR   GenomeRNAi; 7409; -.
DR   Pharos; P15498; Tchem.
DR   PRO; PR:P15498; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P15498; protein.
DR   Bgee; ENSG00000141968; Expressed in granulocyte and 126 other tissues.
DR   ExpressionAtlas; P15498; baseline and differential.
DR   Genevisible; P15498; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140031; F:phosphorylation-dependent protein binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IEA:Ensembl.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0045954; P:positive regulation of natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0008361; P:regulation of cell size; IGI:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IGI:UniProtKB.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0030217; P:T cell differentiation; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd01223; PH_Vav; 1.
DR   CDD; cd00160; RhoGEF; 1.
DR   CDD; cd10405; SH2_Vav1; 1.
DR   CDD; cd11979; SH3_VAV1_1; 1.
DR   CDD; cd11976; SH3_VAV1_2; 1.
DR   Gene3D; 1.10.418.10; -; 1.
DR   Gene3D; 1.20.900.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   IDEAL; IID00652; -.
DR   InterPro; IPR022613; CAMSAP-like_CH_dom.
DR   InterPro; IPR001715; CH-domain.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR037832; PH_Vav.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR003096; SM22_calponin.
DR   InterPro; IPR028530; Vav1.
DR   InterPro; IPR035879; VAV1_SH2.
DR   InterPro; IPR035730; VAV1_SH3_1.
DR   InterPro; IPR035729; VAV1_SH3_2.
DR   PANTHER; PTHR45818:SF2; PTHR45818:SF2; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF11971; CAMSAP_CH; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 2.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00888; SM22CALPONIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00033; CH; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 2.
DR   SUPFAM; SSF47576; SSF47576; 1.
DR   SUPFAM; SSF48065; SSF48065; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50021; CH; 1.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 2.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Guanine-nucleotide releasing factor;
KW   Metal-binding; Phosphoprotein; Proto-oncogene; Reference proteome; Repeat;
KW   SH2 domain; SH3 domain; Zinc; Zinc-finger.
FT   CHAIN           1..845
FT                   /note="Proto-oncogene vav"
FT                   /id="PRO_0000080980"
FT   DOMAIN          1..119
FT                   /note="Calponin-homology (CH)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          194..373
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          402..504
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          592..660
FT                   /note="SH3 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          671..765
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          782..842
FT                   /note="SH3 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   ZN_FING         515..564
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   MOD_RES         826
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         844
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P27870"
FT   VAR_SEQ         187..218
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047563"
FT   VARIANT         739
FT                   /note="T -> M (in dbSNP:rs36097961)"
FT                   /id="VAR_051997"
FT   MUTAGEN         529
FT                   /note="C->R: Abolishes transforming activity."
FT                   /evidence="ECO:0000269|PubMed:2069873"
FT   MUTAGEN         696
FT                   /note="R->L: Loss of interaction with SYK."
FT                   /evidence="ECO:0000269|PubMed:8986718"
FT   CONFLICT        264
FT                   /note="A -> P (in Ref. 6; CAA34383)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        368
FT                   /note="Q -> R (in Ref. 5; BAG62721)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        718
FT                   /note="I -> TV (in Ref. 6)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..13
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   TURN            22..24
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           30..37
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           41..50
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           68..84
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   TURN            90..92
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           96..100
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           105..116
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           119..122
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           145..148
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           158..160
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           173..177
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           191..219
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           221..225
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           230..236
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           240..259
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           261..263
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           266..273
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           276..278
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           279..285
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           287..300
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           302..316
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          317..319
FT                   /evidence="ECO:0007829|PDB:6NF1"
FT   HELIX           322..325
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           328..333
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           336..345
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           350..389
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          390..392
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           397..400
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          403..412
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          420..437
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          440..448
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           449..451
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          452..456
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           458..460
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   TURN            461..463
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          469..475
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          481..488
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           489..506
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   TURN            509..512
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           513..515
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          518..521
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   TURN            530..532
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          538..540
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   STRAND          543..546
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   TURN            547..549
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           555..560
FT                   /evidence="ECO:0007829|PDB:6NEW"
FT   HELIX           666..668
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          669..672
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   HELIX           678..684
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   TURN            685..687
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          692..696
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          700..702
FT                   /evidence="ECO:0007829|PDB:2LCT"
FT   STRAND          706..711
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          714..719
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          721..723
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          726..730
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          735..737
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   HELIX           738..745
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   HELIX           750..752
FT                   /evidence="ECO:0007829|PDB:2CRH"
FT   STRAND          754..756
FT                   /evidence="ECO:0007829|PDB:2LCT"
FT   STRAND          763..766
FT                   /evidence="ECO:0007829|PDB:2CRH"
SQ   SEQUENCE   845 AA;  98314 MW;  AC3BC9736FD2F138 CRC64;
     MELWRQCTHW LIQCRVLPPS HRVTWDGAQV CELAQALRDG VLLCQLLNNL LPHAINLREV
     NLRPQMSQFL CLKNIRTFLS TCCEKFGLKR SELFEAFDLF DVQDFGKVIY TLSALSWTPI
     AQNRGIMPFP TEEESVGDED IYSGLSDQID DTVEEDEDLY DCVENEEAEG DEIYEDLMRS
     EPVSMPPKMT EYDKRCCCLR EIQQTEEKYT DTLGSIQQHF LKPLQRFLKP QDIEIIFINI
     EDLLRVHTHF LKEMKEALGT PGAANLYQVF IKYKERFLVY GRYCSQVESA SKHLDRVAAA
     REDVQMKLEE CSQRANNGRF TLRDLLMVPM QRVLKYHLLL QELVKHTQEA MEKENLRLAL
     DAMRDLAQCV NEVKRDNETL RQITNFQLSI ENLDQSLAHY GRPKIDGELK ITSVERRSKM
     DRYAFLLDKA LLICKRRGDS YDLKDFVNLH SFQVRDDSSG DRDNKKWSHM FLLIEDQGAQ
     GYELFFKTRE LKKKWMEQFE MAISNIYPEN ATANGHDFQM FSFEETTSCK ACQMLLRGTF
     YQGYRCHRCR ASAHKECLGR VPPCGRHGQD FPGTMKKDKL HRRAQDKKRN ELGLPKMEVF
     QEYYGLPPPP GAIGPFLRLN PGDIVELTKA EAEQNWWEGR NTSTNEIGWF PCNRVKPYVH
     GPPQDLSVHL WYAGPMERAG AESILANRSD GTFLVRQRVK DAAEFAISIK YNVEVKHIKI
     MTAEGLYRIT EKKAFRGLTE LVEFYQQNSL KDCFKSLDTT LQFPFKEPEK RTISRPAVGS
     TKYFGTAKAR YDFCARDRSE LSLKEGDIIK ILNKKGQQGW WRGEIYGRVG WFPANYVEED
     YSEYC
//